Biological therapy for ulcerative colitis:An update

作     者：Geom Seog Seo Soo-Cheon Chae 

作者机构：Department of GastroenterologyWonkwang University School of MedicineDigestive Disease Research Institute Department of PathologyWonkwang University School of MedicineDigestive Disease Research Insti-tute 

出 版 物：《World Journal of Gastroenterology》 (世界胃肠病学杂志（英文版）)

年 卷 期：2014年第20卷第37期

页      面：13234-13238页

核心收录：

学科分类：1002[医学-临床医学] 100201[医学-内科学(含：心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 10[医学] 

基　　金：Supported by Grants from Wonkwang University in 2013 

主　　题：Ulcerative colitis Immune dysfunction Biological therapy Remission Clinical trial Inflammatory bowel disease 

摘      要：Of the diverse biological agents used for patients with ulcerative colitis, the anti-tumor necrosis factor-α agents infliximab and adalimumab have been used in large-scale clinical trials and are currently widely used in the treatment of inflammatory bowel disease patients. Recent studies have indicated that golimumab, oral tofacitinib and vedolizumab reportedly achieved good clinical response and remission rates in ulcerative colitis patients. Thus, we believe that the detailed investigation of various studies on clinical trials may provide important information for the selection of appropriate biological agents, and therefore, we have extensively reviewed such trials in the present study.